{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,21]],"date-time":"2026-04-21T02:27:17Z","timestamp":1776738437960,"version":"3.51.2"},"reference-count":26,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2020,11,9]],"date-time":"2020-11-09T00:00:00Z","timestamp":1604880000000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"},{"start":{"date-parts":[[2020,11,9]],"date-time":"2020-11-09T00:00:00Z","timestamp":1604880000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100001809","name":"the National Natural Science Foundation of China","doi-asserted-by":"crossref","award":["Grant No.81772272"],"award-info":[{"award-number":["Grant No.81772272"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"crossref"}]},{"name":"the CAMS Innovation Fund for Medical Science","award":["Grant No. 2017-I2M-3-005"],"award-info":[{"award-number":["Grant No. 2017-I2M-3-005"]}]},{"name":"Beijing Hope Run Special Fund of Cancer Foundation of China","award":["LC2018B16"],"award-info":[{"award-number":["LC2018B16"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Virol J"],"published-print":{"date-parts":[[2020,12]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>The SureX HPV genotyping test (SureX HPV test), which targets the human papillomavirus (HPV) E6\/E7 genes was compared with the Cobas 4800 and Venus HPV tests for detecting 14 high-risk HPV (HR-HPV) types in clinical referral and follow-up patients to evaluate its value for cervical cancer screening.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>Two different populations were enrolled in the study. The first population comprised 185 cases and was used for comparing the SureX HPV test (Health, China) with the Cobas 4800 test (Roche, USA). The second population comprised 290 cases and was used for comparing the SureX HPV test (Health, China) with the Venus HPV test (Zhijiang, China). Polymerase chain reaction (PCR) sequencing was performed for further confirmation of discordant results.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      In the first population, the overall agreement rate was 95.6% for 14 high-risk HPV types. Eight discordant cases were confirmed by PCR sequencing, which showed that the agreement rates were 75.0% between the SureX HPV test and PCR sequencing and 25.0% between the Cobas 4800 test and PCR sequencing (\n                      <jats:italic>P<\/jats:italic>\n                      \u2009&lt;\u20090.01). In the second population, the overall agreement rate was 95.5%. Thirteen discordant cases were confirmed by PCR sequencing, which showed that the agreement rates were 76.9% between the SureX HPV test and PCR sequencing and 23.1% between the Venus HPV test and PCR sequencing (\n                      <jats:italic>P<\/jats:italic>\n                      \u2009&lt;\u20090.01). With cervical intraepithelial neoplasia grade 2+ (CIN2+) as the reference standard, the sensitivity values of the SureX HPV test and the Venus HPV test were 93.5% and 92.0%, (\n                      <jats:italic>P<\/jats:italic>\n                      \u2009&gt;\u20090.05), while the specificity values were 43.3% and 46.7%, respectively (\n                      <jats:italic>P<\/jats:italic>\n                      \u2009&gt;\u20090.05).\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>The SureX HPV test had good consistency with both the Cobas 4800 and Venus HPV tests for 14 HR-HPV types. In addition, it avoided some false negatives and false positives. Therefore, the SureX HPV test can be used for cervical cancer screening.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1186\/s12985-020-01417-8","type":"journal-article","created":{"date-parts":[[2020,11,9]],"date-time":"2020-11-09T07:06:38Z","timestamp":1604905598000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":9,"title":["Evaluation of the SureX HPV genotyping test for the detection of high-risk HPV in cervical cancer screening"],"prefix":"10.1186","volume":"17","author":[{"given":"Baojun","family":"Wei","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ping","family":"Mei","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shengkai","family":"Huang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xueting","family":"Yu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tong","family":"Zhi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Guojing","family":"Wang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xiaotian","family":"Xu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lin","family":"Xiao","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xin","family":"Dong","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4555-2672","authenticated-orcid":false,"given":"Wei","family":"Cui","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2020,11,9]]},"reference":[{"key":"1417_CR1","doi-asserted-by":"publisher","first-page":"394","DOI":"10.3322\/caac.21492","volume":"68","author":"F Bray","year":"2018","unstructured":"Bray F, Ferlay J, Soerjomataram I, Siegel RL, Torre LA, Jemal A. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2018;68:394\u2013424.","journal-title":"CA Cancer J Clin"},{"key":"1417_CR2","first-page":"1","volume":"90","author":"WG Iarc","year":"2007","unstructured":"Iarc WG. Human papillomaviruses. IARC Monogr Eval Carcinog Risks Hum. 2007;90:1\u2013636.","journal-title":"IARC Monogr Eval Carcinog Risks Hum"},{"key":"1417_CR3","doi-asserted-by":"publisher","first-page":"3257939","DOI":"10.1155\/2019\/3257939","volume":"2019","author":"CK Chan","year":"2019","unstructured":"Chan CK, Aimagambetova G. Human papillomavirus infection and cervical cancer: epidemiology, screening, and vaccination-review of current perspectives. J Oncol. 2019;2019:3257939. https:\/\/doi.org\/10.1155\/2019\/3257939.","journal-title":"J Oncol"},{"key":"1417_CR4","doi-asserted-by":"publisher","first-page":"2189","DOI":"10.1517\/14656566.2011.596527","volume":"12","author":"FX Bosch","year":"2011","unstructured":"Bosch FX. Human papillomavirus: science and technologies for the elimination of cervical cancer. Expert Opin Pharmacother. 2011;12:2189\u2013204.","journal-title":"Expert Opin Pharmacother"},{"key":"1417_CR5","doi-asserted-by":"publisher","first-page":"169","DOI":"10.1016\/j.virol.2013.05.038","volume":"445","author":"CB Buck","year":"2013","unstructured":"Buck CB, Day PM, Trus BL. The papillomavirus major capsid protein L1. Virology. 2013;445:169\u201374.","journal-title":"Virology"},{"key":"1417_CR6","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1016\/j.ejogrb.2013.06.027","volume":"170","author":"WA Tjalma","year":"2013","unstructured":"Tjalma WA, Depuydt CE. Cervical cancer screening: which HPV test should be used\u2013L1 or E6\/E7? Eur J Obstet Gynecol Reprod Biol. 2013;170:45\u20136.","journal-title":"Eur J Obstet Gynecol Reprod Biol"},{"key":"1417_CR7","doi-asserted-by":"publisher","first-page":"337","DOI":"10.1016\/0029-7844(94)00399-X","volume":"85","author":"O Lungu","year":"1995","unstructured":"Lungu O, Sun XW, Wright TC Jr, Ferenczy A, Richart RM, Silverstein S. A polymerase chain reaction-enzyme-linked immunosorbent assay method for detecting human papillomavirus in cervical carcinomas and high-grade cervical cancer precursors. Obstet Gynecol. 1995;85:337\u201342.","journal-title":"Obstet Gynecol"},{"key":"1417_CR8","doi-asserted-by":"publisher","first-page":"12","DOI":"10.1002\/(SICI)1096-9896(199909)189:1<12::AID-PATH431>3.0.CO;2-F","volume":"189","author":"JM Walboomers","year":"1999","unstructured":"Walboomers JM, Jacobs MV, Manos MM, Bosch FX, Kummer JA, Shah KV, Snijders PJ, Peto J, Meijer CJ, Mu\u00f1oz N. Human papillomavirus is a necessary cause of invasive cervical cancer worldwide. J Pathol. 1999;189:12\u20139.","journal-title":"J Pathol"},{"key":"1417_CR9","doi-asserted-by":"publisher","first-page":"147","DOI":"10.3322\/caac.21139","volume":"62","author":"D Saslow","year":"2012","unstructured":"Saslow D, Solomon D, Lawson HW, Killackey M, Kulasingam SL, Cain J, Garcia FA, Moriarty AT, Waxman AG, Wilbur DC, et al. American Cancer Society, American Society for Colposcopy and Cervical Pathology, and American Society for Clinical Pathology screening guidelines for the prevention and early detection of cervical cancer. CA Cancer J Clin. 2012;62:147\u201372.","journal-title":"CA Cancer J Clin"},{"key":"1417_CR10","doi-asserted-by":"publisher","first-page":"92","DOI":"10.1186\/s12985-019-1197-6","volume":"16","author":"A Pesic","year":"2019","unstructured":"Pesic A, Krings A, Hempel M, Preyer R, Chatzistamatiou K, Agorastos T, Kaufmann AM. CIN2+ detection of the HPV DNA array genotyping assay in comparison with the Cobas 4800 HPV test and cytology. Virol J. 2019;16:92.","journal-title":"Virol J"},{"key":"1417_CR11","doi-asserted-by":"publisher","first-page":"291","DOI":"10.1128\/CMR.00013-15","volume":"29","author":"EM Burd","year":"2016","unstructured":"Burd EM. Human papillomavirus laboratory testing: the changing paradigm. Clin Microbiol Rev. 2016;29:291\u2013319.","journal-title":"Clin Microbiol Rev"},{"key":"1417_CR12","doi-asserted-by":"publisher","first-page":"518","DOI":"10.1056\/NEJMoa021641","volume":"348","author":"N Mu\u00f1oz","year":"2003","unstructured":"Mu\u00f1oz N, Bosch FX, de Sanjos\u00e9 S, Herrero R, Castellsagu\u00e9 X, Shah KV, Snijders PJ, Meijer CJ. Epidemiologic classification of human papillomavirus types associated with cervical cancer. N Engl J Med. 2003;348:518\u201327.","journal-title":"N Engl J Med"},{"key":"1417_CR13","doi-asserted-by":"publisher","first-page":"5190","DOI":"10.1128\/JVI.02726-07","volume":"82","author":"CB Buck","year":"2008","unstructured":"Buck CB, Cheng N, Thompson CD, Lowy DR, Steven AC, Schiller JT, Trus BL. Arrangement of L2 within the papillomavirus capsid. J Virol. 2008;82:5190\u20137.","journal-title":"J Virol"},{"issue":"Suppl 1","key":"1417_CR14","doi-asserted-by":"publisher","first-page":"S43","DOI":"10.1016\/j.jcv.2004.12.004","volume":"32","author":"A Molijn","year":"2005","unstructured":"Molijn A, Kleter B, Quint W, van Doorn LJ. Molecular diagnosis of human papillomavirus (HPV) infections. J Clin Virol. 2005;32(Suppl 1):S43-51.","journal-title":"J Clin Virol"},{"key":"1417_CR15","doi-asserted-by":"publisher","first-page":"263","DOI":"10.1016\/j.ygyno.2011.07.017","volume":"123","author":"J Shen-Gunther","year":"2011","unstructured":"Shen-Gunther J, Yu X. HPV molecular assays: defining analytical and clinical performance characteristics for cervical cytology specimens. Gynecol Oncol. 2011;123:263\u201371.","journal-title":"Gynecol Oncol"},{"key":"1417_CR16","doi-asserted-by":"publisher","first-page":"5583","DOI":"10.1073\/pnas.90.12.5583","volume":"90","author":"PF Lambert","year":"1993","unstructured":"Lambert PF, Pan H, Pitot HC, Liem A, Jackson M, Griep AE. Epidermal cancer associated with expression of human papillomavirus type 16 E6 and E7 oncogenes in the skin of transgenic mice. Proc Natl Acad Sci USA. 1993;90:5583\u20137.","journal-title":"Proc Natl Acad Sci USA"},{"key":"1417_CR17","doi-asserted-by":"publisher","first-page":"1171","DOI":"10.1515\/CCLM.2005.203","volume":"43","author":"BJ Morris","year":"2005","unstructured":"Morris BJ. Cervical human papillomavirus screening by PCR: advantages of targeting the E6\/E7 region. Clin Chem Lab Med. 2005;43:1171\u20137.","journal-title":"Clin Chem Lab Med"},{"key":"1417_CR18","doi-asserted-by":"publisher","first-page":"277","DOI":"10.1016\/j.jcv.2006.03.013","volume":"36","author":"CC Roberts","year":"2006","unstructured":"Roberts CC, Tadesse AS, Sands J, Halvorsen T, Schofield TL, Dalen A, Skjeldestad FE, Jansen KU. Detection of HPV in Norwegian cervical biopsy specimens with type-specific PCR and reverse line blot assays. J Clin Virol. 2006;36:277\u201382.","journal-title":"J Clin Virol"},{"key":"1417_CR19","first-page":"91","volume":"1845","author":"AC de Freitas","year":"2014","unstructured":"de Freitas AC, Coimbra EC, Leit\u00e3o Mda C. Molecular targets of HPV oncoproteins: potential biomarkers for cervical carcinogenesis. Biochim Biophys Acta. 2014;1845:91\u2013103.","journal-title":"Biochim Biophys Acta"},{"key":"1417_CR20","doi-asserted-by":"publisher","first-page":"550","DOI":"10.1038\/nrc2886","volume":"10","author":"CA Moody","year":"2010","unstructured":"Moody CA, Laimins LA. Human papillomavirus oncoproteins: pathways to transformation. Nat Rev Cancer. 2010;10:550\u201360.","journal-title":"Nat Rev Cancer"},{"key":"1417_CR21","doi-asserted-by":"publisher","first-page":"1048","DOI":"10.1016\/S1470-2045(10)70230-8","volume":"11","author":"S de Sanjose","year":"2010","unstructured":"de Sanjose S, Quint WG, Alemany L, Geraets DT, Klaustermeier JE, Lloveras B, Tous S, Felix A, Bravo LE, Shin HR, et al. Human papillomavirus genotype attribution in invasive cervical cancer: a retrospective cross-sectional worldwide study. Lancet Oncol. 2010;11:1048\u201356.","journal-title":"Lancet Oncol"},{"key":"1417_CR22","doi-asserted-by":"publisher","first-page":"2349","DOI":"10.1002\/ijc.27485","volume":"131","author":"P Guan","year":"2012","unstructured":"Guan P, Howell-Jones R, Li N, Bruni L, de Sanjos\u00e9 S, Franceschi S, Clifford GM. Human papillomavirus types in 115,789 HPV-positive women: a meta-analysis from cervical infection to cancer. Int J Cancer. 2012;131:2349\u201359.","journal-title":"Int J Cancer"},{"key":"1417_CR23","doi-asserted-by":"publisher","first-page":"1705","DOI":"10.1007\/s10552-009-9422-z","volume":"20","author":"W Chen","year":"2009","unstructured":"Chen W, Zhang X, Molijn A, Jenkins D, Shi JF, Quint W, Schmidt JE, Wang P, Liu YL, Li LK, et al. Human papillomavirus type-distribution in cervical cancer in China: the importance of HPV 16 and 18. Cancer Causes Control. 2009;20:1705\u201313.","journal-title":"Cancer Causes Control"},{"key":"1417_CR24","doi-asserted-by":"publisher","first-page":"S2","DOI":"10.1016\/j.ygyno.2007.07.067","volume":"107","author":"M Steben","year":"2007","unstructured":"Steben M, Duarte-Franco E. Human papillomavirus infection: epidemiology and pathophysiology. Gynecol Oncol. 2007;107:S2-5.","journal-title":"Gynecol Oncol"},{"key":"1417_CR25","doi-asserted-by":"publisher","first-page":"1867","DOI":"10.1128\/JCM.00181-12","volume":"50","author":"A Szarewski","year":"2012","unstructured":"Szarewski A, Mesher D, Cadman L, Austin J, Ashdown-Barr L, Ho L, Terry G, Liddle S, Young M, Stoler M, et al. Comparison of seven tests for high-grade cervical intraepithelial neoplasia in women with abnormal smears: the predictors 2 study. J Clin Microbiol. 2012;50:1867\u201373.","journal-title":"J Clin Microbiol"},{"key":"1417_CR26","doi-asserted-by":"publisher","first-page":"263","DOI":"10.1093\/ajcp\/aqy124","volume":"151","author":"M Nakamura","year":"2019","unstructured":"Nakamura M, Nakade K, Orisaka S, Iwadare J, Mizumoto Y, Fujiwara H. Comparison study of BD onclarity HPV with digene HC2 high-risk HPV DNA test and Roche Cobas 4800 HPV for detecting high-risk human papillomavirus in Japan. Am J Clin Pathol. 2019;151:263\u20139.","journal-title":"Am J Clin Pathol"}],"container-title":["Virology Journal"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s12985-020-01417-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1186\/s12985-020-01417-8\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s12985-020-01417-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,11,9]],"date-time":"2020-11-09T19:47:30Z","timestamp":1604951250000},"score":1,"resource":{"primary":{"URL":"https:\/\/virologyj.biomedcentral.com\/articles\/10.1186\/s12985-020-01417-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,11,9]]},"references-count":26,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2020,12]]}},"alternative-id":["1417"],"URL":"https:\/\/doi.org\/10.1186\/s12985-020-01417-8","relation":{"has-preprint":[{"id-type":"doi","id":"10.21203\/rs.3.rs-32573\/v1","asserted-by":"object"},{"id-type":"doi","id":"10.21203\/rs.3.rs-32573\/v2","asserted-by":"object"}]},"ISSN":["1743-422X"],"issn-type":[{"value":"1743-422X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,11,9]]},"assertion":[{"value":"3 June 2020","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"22 September 2020","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"9 November 2020","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The study was approved by the Ethics Committee at National Cancer Center\/Cancer Hospital.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare that they have no competing interests.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"171"}}